Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.40 |
| ▸ | CA2 | P00918 | 6/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL461597 | 0.87 | CA1 (0.43) | CA1CA2CA12CA7CA13 | |
| SCHEMBL1032872 | 0.81 | CA1 (0.40) | CA1CA2CA12CA7CA13 | |
| Benzene SCHEMBL29240836 | 0.81 | CA1 (0.40) | CA1CA2CA12CA7CA13 | |
| SCHEMBL30952527 | 0.81 | CA1 (0.40) | CA1CA2CA12CA7CA13 | |
| SCHEMBL5814455 | 0.80 | CA1 (0.38) | CA1CA2CA12CA7CA13 | |
| Cyanide SCHEMBL28063239 | 0.79 | CA1 (0.39) | CA1CA2CA12CA7CA13 | |
| SCHEMBL8919707 | 0.75 | CA1 (0.40) | CA1CA2CA12CA7CA13 | |
| SCHEMBL5515482 | 0.75 | CA12 (0.35) | CA1CA2CA12CA7CA13 | |
| SCHEMBL24347981 | 0.75 | CA1 (0.43) | CA1CA2CA12CA7CA13 | |
| SCHEMBL8053563 | 0.75 | CA1 (0.36) | CA1CA2CA12CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036621-A | Fluorine substituted benzimidazolyl aniline compound and synthetic method and application thereof | 中茂绿能科技(西安)有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-1956008-B1 | ORGANIC COMPOUND, CHARGE-TRANSPORTING MATERIAL, COMPOSITION FOR CHARGE-TRANSPORTING MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE | MITSUBISHI CHEM CORP (JP) | 2012-03-28 | — | — | EP | disclosed |
| US-8022617-B2 | Organic compound, charge-transporting material, composition for charge-transporting material and organic electroluminescent device | MITSUBISHI CHEMICAL CORPORATION (JP) | 2011-09-20 | — | — | US | disclosed |
| EP-2350027-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-08-03 | — | — | EP | disclosed |
| CN-102143951-A | Tri-substituted pyrimidine compounds and their use as PDE10 inhibitors | MITSUBISHI TANABE PHARMA CORP | 2011-08-03 | — | — | CN | disclosed |
| US-20110160206-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-06-30 | — | — | US | disclosed |
| WO-2010027097-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-11 | — | — | WO | disclosed |
| US-20090284134-A1 | ORGANIC COMPOUND, CHARGE-TRANSPORTING MATERIAL, COMPOSITION FOR CHARGE-TRANSPORTING MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-11-19 | — | — | US | disclosed |
| CN-100478364-C | Ethylene polymer and molded article obtained therefrom | MITSUI CHEMICALS INC (JP) | 2009-04-15 | — | — | CN | disclosed |
| CN-101287713-A | Organic compound, charge transport material, composition for charge transport material, and organic electroluminescent element | MITSUBISHI CHEM CORP (JP) | 2008-10-15 | — | — | CN | disclosed |
| US-20060135712-A1 | Ethylened polymer and molded object obtained therefrom | MITSUI CHEMICALS, INC. (JP) | 2006-06-22 | — | — | US | disclosed |
| CN-1732189-A | Ethylene polymer and molded article obtained therefrom | MITSUI CHEMICALS INC (JP) | 2006-02-08 | — | — | CN | disclosed |
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | AXYS PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | US | disclosed |
| US-6562854-B2 | Antiinflammatory agents; respiratory system disorders | AXYS PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | Celera Corporation | 2001-12-20 | — | — | US | disclosed |
| EP-1117651-A1 | NEW BIS-BENZIMIDAZOLES | Bayer Aktiengesellschaft (DE) | 2001-07-25 | — | — | EP | disclosed |
| EP-1019382-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SERINE PROTEASE, PARTICULARLY TRYPTASE, ACTIVITY | AXYS PHARMACEUTICALS, INC. (US) | 2000-07-19 | — | — | EP | disclosed |
| CN-1251579-A | Compound and compositions for treating diseases associated with serine protease, particularly tryptase, activity | AXYS PHARM CORP (US) | 2000-04-26 | — | — | CN | disclosed |
| WO-2000020401-A1 | NEW BIS-BENZIMIDAZOLES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-04-13 | — | — | WO | disclosed |
| WO-1998045275-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SERINE PROTEASE, PARTICULARLY TRYPTASE, ACTIVITY | AXYS PHARMACEUTICALS CORPORATION (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053779-A1 | Novel compounds and compositions for treating diseases asociated with protease activity | CMA1, CPA3, TPSG1 | CA1 377/4885CA2 395/4885CA12 546/4885 |
| US-20110160206-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PDE10A, PDE12, PDE9A | CA1 3341/4885CA2 344/4885CA12 3477/4885 |
| US-20090284134-A1 | ORGANIC COMPOUND, CHARGE-TRANSPORTING MATERIAL, COMPOSITION FOR CHARGE-TRANSPORTING MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE | SLCO4C1, SLCO2A1, SLCO2B1 | CA1 3823/4885CA2 2795/4885CA12 4073/4885 |
| US-20030212120-A1 | Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders | CMA1, TPSG1, TPSD1 | CA1 633/4885CA2 573/4885CA12 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.